Supreme Court Upholds Mail Access to Abortion Pill Mifepristone

The U.S. Supreme Court has issued an unsigned order maintaining nationwide mail access to the abortion medication mifepristone, temporarily setting aside a lower court ruling that sought to reinstate in-person dispensing requirements. This decision ensures that patients can continue to obtain the drug via telehealth and mail while litigation challenging the Food and Drug Administration's relaxed policies proceeds. The case was initiated by Louisiana, which argued that remote access allows out-of-state providers to evade its strict abortion bans, resulting in thousands of unlawful procedures within the state. Conservative Justices Samuel Alito and Clarence Thomas dissented from the majority's decision. Pharmaceutical manufacturers Danco Laboratories and GenBioPro had urged the Court to block the appellate ruling, citing confusion and disruption to healthcare services. The FDA, which formally allowed mail-order prescriptions in 2023 following pandemic-era adjustments, did not take a position in this specific appeal. This ruling preserves broad access to mifepristone, which is used in a significant majority of clinician-provided abortions in the United States, amidst ongoing legal and political debates following the overturning of Roe v. Wade.